We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal judge has thrown out Amarin’s complaint against Hikma Pharmaceuticals over the latter’s alleged patent infringement by its generic version of Vascepa (icosapent ethyl). Read More
France’s Sanofi and UK-based Exscientia have struck a deal potentially worth $5.2 billion to develop up to 15 new therapies for cancer and immunology indications using Exscientia’s artificial intelligence-based drug discovery platform. Read More
The FDA will soon decide whether Eli Lilly’s and Innovent Biologics’ immunotherapy sintilimab can get the go-ahead in the U.S. for the treatment of lung cancer. Read More
A federal judge in Texas has ruled that the FDA must by the end of this month make public 12,000 pages of the data it used to make decisions about approvals for Pfizer/BioNTech’s COVID-19 vaccine — and then release 55,000 pages every 30 days after that until all 450,000 requested pages are public. Read More
Tirzepatide, Eli Lilly’s potential dual-molecule blockbuster for type 2 diabetes (T2D), should be priced at $5,500 to $7,500 per year to be a cost-effective therapeutic option, according to the Institute for Clinical and Economic Review (ICER). Read More
In a collaboration potentially valued at $1.9 billion, Amgen is teaming up with Cambridge, Mass.-based Generate Biomedicines to develop protein therapeutics for up to five clinical targets. Read More